The Multiple Facets of Thrombotic Microangiopathies - European Medical Journal

Continue

The Multiple Facets of Thrombotic Microangiopathies

Hematology
Download PDF

Summary of Presentations from the Alexion-Sponsored Symposium, held at the 19th EHA Congress, Milan, Italy, on 12th June 2014

Chairperson:
Pier Mannuccio Mannucci1
Speakers:
Paul Coppo,2 Javier de la Rubia,3 Thorsten Feldkamp4

1. Cà Granda Maggiore Policlinico Hospital Foundation, Milan, Italy 
2. Hôpital Saint-Antoine, Paris, France 
3. Hospital La Fe, Valencia, Spain 
4. University Hospital Schleswig Holstein, Christian-Albrechts-University, Kiel, Germany

Disclosure:

Prof de la Rubia declares speaker fees, consultancy, funding support or sponsorship from Alexion Pharma International. Prof Coppo declares speaker fees, consultancy, funding support, sponsorship, or stocks/shares from Alexion Pharma International, Roche International, and Baxter International. Prof Feldkamp has received speaker fees, consultancy, funding support, or sponsorship from Alexion Pharma International and Novartis. Prof Mannucci received speaker fees from Alexion.

Acknowledgements:

Writing assistance provided by Dr Saroshi Amirthalingam, ApotheCom ScopeMedical.

Support:

The publication of this article was funded by Alexion Pharma International. The views and opinions expressed are those of the authors and not necessarily of Alexion.

Citation:
EMJ Hema. ;1[1]:50-58. DOI/10.33590/emjhematol/10310448. https://doi.org/10.33590/emjhematol/10310448.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The Alexion satellite symposium was introduced by Prof Pier Mannuccio Mannucci who provided an introduction to the history of thrombotic microangiopathies (TMAs). Prof Paul Coppo gave an overview of TMAs and the differential diagnosis of atypical hemolytic-uraemic syndrome (aHUS) and thrombotic thrombocytopaenic purpura (TTP). He emphasised the importance of a suitable differential diagnosis in order to initiate an appropriate treatment as soon as possible, eventually allowing better patient outcomes. Prof Javier de la Rubia discussed the role of the complement pathway and how genetic abnormalities can lead to dysregulation in aHUS. Prof Thorsten Feldkamp concluded by giving an overview of the latest clinical trial data on the efficacy and safety of eculizumab in the management of aHUS.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given